|
|
Home > Healthcare > Medical > Diagnostics
Oncology Partnering Agreements in Pharma, Biotech and Diagnostics
|
| Published Date:
June 2009
Published By:
CurrentPartnering
Page Count:
471
Order Code:
R3504-114
|
|
|
|
- Executive Summary
- Chapter 1 - Introduction
- Chapter 2 - Overview of oncology dealmaking
- 2.1. Introduction
- 2.2. The anatomy of oncology partnering
- 2.2.1. The anatomy of an oncology deal
- 2.2.1.a. Case study 1: Celgene - Array Biopharma - September 2007
- 2.2.1.b. Case study 2: Merck - Ariad - July 2007
- 2.2.1.c. Case study 3: UCB - ImClone - August 2005
- 2.3. Typical partnering terms
- 2.3.1. Headline deal values
- 2.3.2. Upfront payments
- 2.3.3. Milestone payments
- 2.3.4. Royalties
- Chapter 3 - Trends in oncology dealmaking
- 3.1. Introduction
- 3.2. Oncology partnering over the years
- 3.3. Most active oncology dealmakers
- 3.4. Bigpharma oncology dealmaking activity
- 3.5. Bigpharma not active in oncology
- 3.6. Oncology partnering by stage of development
- 3.7. Oncology partnering by deal type
- 3.7.1. Co-promotion oncology partnering
- 3.7.2. Option and evaluation oncology partnering
- 3.8. Oncology partnering by disease type
- 3.8.1. Trends in broad focus oncology partnering
- Chapter 4 - Leading oncology deals
- 4.1. Introduction
- 4.2. Top oncology deals by value
- 4.3. Top oncology involving bigpharma
- Chapter 5 - Bigpharma oncology deals
- 5.1. Introduction
- 5.2. How to use bigpharma oncology partnering deals
- 5.3. Bigpharma partnering company profiles
- Abbott
- Actavis
- Alcon Labs
- Allergan
- Amgen
- Astellas
- AstraZeneca
- Baxter International
- Bayer
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Cephalon
- Chugai
- CSL
- Daiichi Sankyo
- Dainippon Sumitomo
- Eisai
- Eli Lilly
- Forest Laboratories
- Genentech
- Genzyme
- Gilead Sciences
- GlaxoSmithKline
- Hospira
- Johnson & Johnson
- Lundbeck
- Menarini
- Merck & Co
- Merck - Serono
- Mitsubishi Tanabe
- Mylan
- Novartis
- Novo Nordisk
- Nycomed Pharma
- Otsuka
- Pfizer
- Procter & Gamble
- Ratiopharm
- Roche
- Sanofi-Aventis
- Schering Plough
- Servier
- Shire
- Solvay
- Takeda
- Teva
- UCB
- Watson
- Wyeth
- Chapter 6 - Oncology dealmaking directory
- 6.1. Introduction
- 6.2. Company A-Z
- 6.3. By stage of development
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Registration
- Marketed
- 6.4. By deal type
- Asset and product purchase
- Collaborative R&D
- Co-development
- Co-marketing
- Co-promotion
- Development
- Distribution
- Joint venture
- Licensing
- M&A
- Manufacturing
- Marketing
- Promotion
- Option
- Research
- Supply
- 6.5. By oncology type
- Bladder
- Breast
- Brain
- Cervical
- Colorectal
- Gastrointestinal
- Head and neck
- Kidney
- Leukemia
- Liver
- Lung
- Lymphoma
- Melanoma
- Multiple myeloma
- Ovarian
- Pancreatic
- Prostate
- Solid tumour
- Broad focus
- Diagnostics
- Drug delivery
- Chapter 7 - Oncology partnering resource center
- 7.1. Online oncology partnering
- 7.2. Oncology partnering events
- 7.3. Further reading on oncology dealmaking
- Appendices
- Appendix 1 - Deal type definitions
- Appendix 2 - Example oncology partnering agreement
- About CurrentPartnering
- Recent titles from CurrentPartnering
- Figures in report
- Figure 1: Components of the typical oncology deal structure
- Figure 2: Discovery stage average payment terms
- Figure 3: Average royalty rates payment terms
- Figure 4: Oncology partnering since 2000
- Figure 5: Most active oncology dealmakers 2003-2008
- Figure 6: Bigpharma - top 50 - oncology deals 2003 to 2008
- Figure 7: Inactive oncology dealmakers 2003-2008
- Figure 8: Oncology partnering by stage of development since 2003
- Figure 9: Oncology partnering by deal type since 2003
- Figure 10: Oncology co-promotion deals since 2003
- Figure 11: Oncology option deals since 2003
- Figure 12: Oncology partnering by disease type from 2003
- Figure 13: Trends in broad focus oncology partnering since 2003
- Figure 14: Top oncology deals by value since 2000
- Figure 15: Top 50 oncology deals signed by bigpharma value since 2000
- Figure 16: Online partnering resources
- Figure 17: Forthcoming partnering events
- Figure 18: Deal type definitions
- Figure 19: Oncology partnering between Daiichi Sankyo and ArQule, November 2008
|
Similar Products
• Testing Laboratories
Published Nov 2009 by First Research, Inc.
• Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads
Published Nov 2009 by Kalorama Information
• Infectious Disease Testing Market: US, Europe, Japan--Emerging Opportunities and Business Strategies
Published Nov 2009 by Venture Planning Group
• 2009 Worldwide Diagnostics Market Research Bundle
Published Oct 2009 by Kalorama Information
• Three Alternative Scenarios Of The Future In Vitro Diagnostics Market 2009-2018
Published Oct 2009 by Venture Planning Group
• Preventive Healthcare Technologies, Products and Markets
Published Oct 2009 by BCC Research
• The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets
Published Oct 2009 by Kalorama Information
• Veterinary Diagnostics Markets
Published Oct 2009 by Kalorama Information
• Innovations in Oncology Diagnostics: Technological advances, growth opportunities and future market outlook
Published Oct 2009 by Business Insights
|
|
|
|
0 items
